Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyglucose SCHEMBL29105105 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL148114 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL2315642 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL3019708 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL2065929 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL120125 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL4480352 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL10386937 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL200714 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL635056 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2019 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095027-A | Modified maleated natural oil-based reaction products and slurry compositions containing the same | — | 2026-05-26 | — | — | CN | claimed |
| US-12636299-B2 | Terpenoid derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-05-26 | — | — | US | claimed |
| CN-122055416-A | Dispersants for carbon nanotubes and carbon nanotube compositions comprising hydrophobically and hydrophilically modified maleated natural oil salts | 埃斯普投资有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260132163-A1 | BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2026-05-14 | — | — | US | claimed |
| EP-4704575-A2 | HYDROPHOBIC AND HYDROPHILIC MODIFIED MALEATED NATURAL OILS, SALTS AND ITS AGRICULTURAL COMPOSITIONS AND METHODS OF USE | ISP Investments LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12545699-B2 | Bivalent LECA inhibitors targeting biofilm formation of Pseudomonas aeruginosa | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-02-10 | — | — | US | claimed |
| EP-4683510-A1 | HYDROPHOBIC AND HYDROPHILIC MODIFIED MALEATED NATURAL OILS AND AGRICULTURAL COMPOSITIONS THEREOF | ISP Investments LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4683973-A2 | DISPERSANT COMPOSITIONS COMPRISING HYDROPHOBIC AND HYDROPHILIC MODIFIED MALEATED NATURAL OILS, AND APPLICATIONS THEREOF | ISP Investments LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | claimed |
| US-20260002090-A1 | HYDROPHOBIC AND HYDROPHILIC MODIFIED MALEATED NATURAL OILS AND COMPOSITIONS THEREOF | ISP INVESTMENTS LLC (US) | 2026-01-01 | — | — | US | claimed |
| WO-1993006227-A1 | KETOALDONIC ACIDS HAVING FORMED STEREOGENIC CENTERS OF R CONFIGURATION: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0178602-B1 | TREATMENT FOR TISSUE DEGENERATIVE INFLAMMATORY DISEASE | Peritain, Ltd. (US) | 1992-05-06 | — | — | EP | claimed |
| EP-0441483-A2 | Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors | BAYLOR COLLEGE OF MEDICINE (US) | 1991-08-14 | — | — | EP | claimed |
| EP-0390783-A1 | METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-10 | — | — | EP | claimed |
| US-4937077-A | Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose | EASTMAN KODAK COMPANY (US) | 1990-06-26 | — | — | US | claimed |
| WO-1989002224-A1 | METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE | EASTMAN KODAK COMPANY (US) | 1989-03-23 | — | — | WO | claimed |
| US-4772591-A | ASCORBIC ACID, CALCIUM SOURCE, ANTIINFLAMMATORY AGENT | PERITAIN, LTD. (US) | 1988-09-20 | — | — | US | claimed |
| EP-0235085-A1 | 13-Beta-sugar derivatives of milbemycine, their preparation and use as ekto- and endo-parasitic agents for treatment of animals and plants | CIBA-GEIGY AG (CH) | 1987-09-02 | — | — | EP | claimed |
| US-4647453-A | Treatment for tissue degenerative inflammatory disease | PERITAIN, LTD. (US) | 1987-03-03 | — | — | US | claimed |
| EP-0178602-A2 | Treatment for tissue degenerative inflammatory disease | Peritain, Ltd. (US) | 1986-04-23 | — | — | EP | claimed |